Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SurVaxM in Metastatic Neuroendocrine Tumors
NCT03879694Phase 1Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jun 2019
- Primary completion
- Feb 2025
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SurVaxM in Neuroendocrine Neoplasm (NEN), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Incidence of adverse events at 15 months. Started Jun 2019; status: completed.
02
Drugs
SurVaxM
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT03879694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03879694.